← SGLT2 inhibitors × cardiovascular events

TrialCirculation2019

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Kenneth W Mahaffey et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT02065791. The trial’s primary report, PMID 30990260, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedrandomised · 4,401 people · 2019

Randomised comparison

Reduced cardiovascular events

Doesn’t vote: a later paper about the trial

−20%−33% to −5%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.80, 95% CI 0.67–0.95

Randomised comparison

Reduced cardiovascular events

Doesn’t vote: a later paper about the trial

−32%−51% to −6%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.68, 95% CI 0.49–0.94

Range includes no effect

No clear effect on cardiovascular events

Doesn’t vote: a later paper about the trial

−15%−31% to +6%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.69–1.06

Three numbers in the abstract

the abstract, start to end

… events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.800.67–0.95
Cardiovascular events
HR 0.680.49–0.94
Cardiovascular events
HR 0.850.69–1.06
SGLT2 inhibitorsCardiovascular events
1 / 3

129 papers cite itlatest 60 shown

2019
…
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

NCT02065791phase 34,401 enrolled2014a later paper about itNCT04450576200 enrolled2019
Full record →Abstract, authors, funding and every citing paper · PMID 31291786